#USA #Karyopharm #XPOVIO #Newton #KPTI

Karyopharm Therapeutics Announces New Inducement Grants

In a significant development for its workforce, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a prominent player in the pharmaceutical industry focusing on innovative cancer therapies, has disclosed the grant of restricted stock units (RSUs) as part of its employee incentive strategy. On September 2, 2025, Karyopharm reported the distribution of a total of 466 RSUs to two recently recruited personnel, reinforcing its commitment to attracting skilled talent in the competitive biotech landscape.

Understanding the Incentive Plan

These stock units were awarded under Karyopharm's 2022 Inducement Stock Incentive Plan, which has been designed to provide incentives that are crucial for new employees joining the company. The RSUs are structured to vest over a three-year period, with one-third of the awarded shares becoming vested on each of the three anniversaries following the grant date of August 31, 2025. Such a vesting schedule not only aligns with industry standards but also emphasizes Karyopharm's dedication to employee retention and long-term commitment.

Moreover, the vesting of these units is contingent on the employees maintaining their roles at Karyopharm, ensuring that they remain aligned with the company’s goals and objectives.

Provisions for Change in Control Events

Notably, the RSUs have an additional provision that allows for their immediate exercisability if a